LEAD-452 / Trimerbody Pharma - LARVOL DELTA

Pharmacokinetics and safety of LEAD-452, an EGFR-specific 4-1BB-agonistic trimerbody in non-human primates. (PubMed, Toxicol Appl Pharmacol) - "In addition, neither IgM nor IgG-based anti-drug antibodies were detected in serum samples from NHP during the study, regardless of the dose of LEAD-452 administered. These results support the clinical development of LEAD-452 for the treatment of solid tumors."

Journal • PK/PD data • Hematological Disorders • Hepatology • Neutropenia • Oncology • Solid Tumor • Thrombocytopenia • EGFR